Biovica International AB (publ)
SSE:BIOVIC-B.ST
2.34 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 7.29 | 3.384 | 2.045 | 2.077 | 1.671 | 3.005 | 2.723 | 0.632 | 2.432 | 0.459 | 4.045 |
| Cost of Revenue
| 128.275 | -1.233 | -2.621 | -3.193 | -6.815 | -5.632 | -5.58 | -4.46 | -4.37 | -3.666 | 0.442 |
| Gross Profit
| -120.985 | 4.617 | 4.666 | 5.27 | 8.486 | 8.637 | 8.303 | 5.092 | 6.802 | 4.125 | 3.603 |
| Gross Profit Ratio
| -16.596 | 1.364 | 2.282 | 2.537 | 5.078 | 2.874 | 3.049 | 8.057 | 2.797 | 8.987 | 0.891 |
| Reseach & Development Expenses
| 5.088 | 5.35 | 13.002 | 7.58 | 2.619 | 1.452 | 1.299 | 1.299 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 15.332 | 15.386 | 11.962 | 9.503 | 9.668 | 8.338 | 7.1 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 123.521 | 106.685 | 59.348 | 15.332 | 15.386 | 11.962 | 9.503 | 9.668 | 8.338 | 7.1 | 8.066 |
| Other Expenses
| 134.507 | 0 | 0 | 30.348 | 22.915 | 18.659 | 16.769 | 10.864 | 2.28 | 0.728 | 0 |
| Operating Expenses
| 5.088 | 115.541 | 65.965 | 45.68 | 38.301 | 30.621 | 26.272 | 20.532 | 13.682 | 11.351 | 8.187 |
| Operating Income
| -126.073 | -110.457 | -60.101 | -40.181 | -29.816 | -21.718 | -17.956 | -14.839 | -4.599 | -6.498 | -4.583 |
| Operating Income Ratio
| -17.294 | -32.641 | -29.389 | -19.346 | -17.843 | -7.227 | -6.594 | -23.479 | -1.891 | -14.157 | -1.133 |
| Total Other Income Expenses Net
| 1.937 | 0.245 | 0.227 | 1.023 | -0.444 | 0.46 | -0.054 | -0.009 | 1.849 | -0.545 | -0.788 |
| Income Before Tax
| -124.136 | -110.68 | -59.991 | -39.386 | -30.259 | -21.524 | -18.01 | -14.848 | -5.031 | -7.043 | -5.372 |
| Income Before Tax Ratio
| -17.028 | -32.707 | -29.335 | -18.963 | -18.108 | -7.163 | -6.614 | -23.494 | -2.069 | -15.344 | -1.328 |
| Income Tax Expense
| 0.687 | -0.187 | 0.012 | 0.096 | 0.059 | 0.032 | 0.054 | 0.009 | -1.849 | 0.545 | 0 |
| Net Income
| -124.823 | -110.492 | -60.003 | -39.483 | -30.318 | -21.556 | -18.064 | -14.857 | -5.031 | -7.043 | -5.372 |
| Net Income Ratio
| -17.122 | -32.651 | -29.341 | -19.01 | -18.144 | -7.173 | -6.634 | -23.508 | -2.069 | -15.344 | -1.328 |
| EPS
| -2.14 | -2.98 | -1.96 | -1.29 | -1.2 | -1.14 | -1.02 | -0.84 | -0.28 | -0.4 | -0.3 |
| EPS Diluted
| -2.14 | -2.98 | -1.96 | -1.29 | -1.2 | -1.14 | -0.99 | -0.82 | -0.28 | -0.4 | -0.3 |
| EBITDA
| -121.732 | -102.549 | -54.605 | -33.184 | -25.646 | -18.694 | -15.218 | -13.023 | -3.235 | -5.179 | -3.999 |
| EBITDA Ratio
| -16.698 | -30.304 | -26.702 | -15.977 | -15.348 | -6.221 | -5.589 | -20.606 | -1.33 | -11.283 | -0.989 |